A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome

Health Technology Assessment

Volumn 18, Issue 58, 2014, Pages 1-406

  Snowsill, Tristan ^a   Huxley, Nicola ^a   Hoyle, Martin ^a   Jones Hughes, Tracey ^a   Coelho, Helen ^a   Cooper, Chris ^a   Frayling, Ian ^b   Hyde, Chris ^a  

^a UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; B RAF KINASE; FLUOROURACIL; FOLINIC ACID;

ABDOMINAL HYSTERECTOMY; ARTICLE; BRAF GENE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CLINICAL EFFECTIVENESS; COLONOSCOPY; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG COST; EARLY DIAGNOSIS; ECONOMIC EVALUATION; ENDOMETRIUM CANCER; GENETIC COUNSELING; GENETIC SCREENING; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; LIFE EXPECTANCY; METHYLATION; MICROSATELLITE INSTABILITY; MORBIDITY; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT; PREVALENCE; RISK FACTOR; RISK REDUCTION; SALPINGOOOPHORECTOMY; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SHORT FORM 36; SURVIVAL TIME; SYSTEMATIC REVIEW; AGED; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; COST BENEFIT ANALYSIS; ECONOMICS; GENETICS; MIDDLE AGED; PROCEDURES;

AGED; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; COST-BENEFIT ANALYSIS; GENETIC TESTING; HUMANS; MIDDLE AGED;

EID: 84907992078     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta18580     Document Type: Article

References (304)

1. Vasen HFA, Moslein G, Alonso A, Bernstein I, Bertario L, Blanco I, et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 2007; 44: 353-62. http://dx. doi. org/10. 1136/jmg. 2007. 048991.
2. Bonadona V, Bonaiti B, Olschwang S, Grandjouan S, Huiart L, Longy M, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 2011; 305: 2304-10. http://dx. doi. org/10. 1001/jama. 2011. 743.
3. Chung DC, Rustgi AK. The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications. Ann Intern Med 2003; 138: 560-70. http://dx. doi. org/10. 7326/0003-4819-138-7-200304010-00012.
4. Bonis PA, Trikalinos TA, Chung M, Chew P, Ip S, DeVine DA, et al. Hereditary nonpolyposis colorectal cancer: diagnostic strategies and their implications. Evid Rep Technol Assess (Full Rep) 2007: 1-180.
5. Vasen H, Blanco I, Aktan-Collan K, Gopie J, Alonso A, Aretz S, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 2013; 62: 812-23. http://dx. doi. org/10. 1136/gutjnl-2012-304356.
6. Surveillance, Epidemiology, and End Results (SEER) Program. SEER Cancer Statistics Factsheets: Kidney and Renal Pelvis Cancer. Bethesda, MD: National Cancer Institute; 2014. URL: http://seer. cancer. gov/statfacts/html/kidrp. html (accessed August 2014).
7. Surveillance, Epidemiology, and End Results (SEER) Program. SEER Cancer Statistics Factsheets: Bladder Cancer. Bethesda, MD: National Cancer Institute; 2014. URL: http://seer. cancer. gov/statfacts/html/urinb. html (accessed August 2014).
8. Cancer Research UK. Lifetime Risk of Cancer. 2013. URL: www. cancerresearchuk. org/cancer-info/cancerstats/incidence/risk (accessed July 2014).
9. Cairns SR, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJ, Evans GD, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010; 59: 666-89. http://dx. doi. org/10. 1136/gut. 2009. 179804.
10. Vasen HFA, Moslein G, Alonso A, Aretz S, Bernstein I, Bertario L, et al. Recommendations to improve identification of hereditary and familial colorectal cancer in Europe. Fam Cancer 2010; 9: 109-15. http://dx. doi. org/10. 1007/s10689-009-9291-3.
11. Shia J, Klimstra DS, Nafa K, Offit K, Guillem JG, Markowitz AJ, et al. Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms. Am J Surg Pathol 2005; 29: 96-104. http://dx. doi. org/10. 1097/01. pas. 0000146009. 85309. 3b.
12. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Nat Cancer Inst 2004; 96: 261-8. http://dx. doi. org/10. 1093/jnci/djh034.
13. Evaluation of Genomic Applications in Practice and Prevention Working Group. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 2009; 11: 35-41. http://dx. doi. org/10. 1097/GIM. 0b013e31818fa2ff.
14. Aarnio M, Mustonen H, Mecklin JP, Jarvinen HJ. Prognosis of colorectal cancer varies in different high-risk conditions. Ann Med 1998; 30: 75-80. http://dx. doi. org/10. 3109/07853899808999387.
15. Aarnio M, Mecklin JP, Aaltonen LA, Nystrom-Lahti M, Jarvinen HJ. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 1995; 64: 430-3. http://dx. doi. org/10. 1002/ijc. 2910640613.
16. Jarvinen HJ, Mecklin JP, Sistonen P. Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 1995; 108: 1405-11. http://dx. doi. org/10. 1016/0016-5085(95)90688-6.
17. Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. The Lancet 2011; 378: 2081-7. http://dx. doi. org/10. 1016/S0140-6736 (11)61049-0.
18. Muller A, Giuffre G, Edmonston TB, Mathiak M, Roggendorf B, Heinmoller E, et al. Challenges and pitfalls in HNPCC screening by microsatellite analysis and immunohistochemistry. J Mol Diagn 2004; 6: 308-15. http://dx. doi. org/10. 1016/S1525-1578(10)60526-0.
19. Brice P. Biomarkers in Familial Colorectal Cancer Screening. Expert Workshop, 14th February 2006. Cambridge: Public Health Genetics Unit; 2006. URL: www. phgfoundation. org/file/2743/(accessed August 2014).
20. Barrow E, Evans DG, McMahon R, Hill J, Byers R. A comparative study of quantitative immunohistochemistry and quantum dot immunohistochemistry for mutation carrier identification in Lynch syndrome. J Clin Pathol 2011; 64: 208-14. http://dx. doi. org/10. 1136/jcp. 2010. 084418.
21. Niessen RC, Berends MJ, Wu Y, Sijmons RH, Hollema H, Ligtenberg MJ, et al. Identification of mismatch repair gene mutations in young patients with colorectal cancer and in patients with multiple tumours associated with hereditary non-polyposis colorectal cancer. Gut 2006; 55: 1781-8. http://dx. doi. org/10. 1136/gut. 2005. 090159.
22. Brown ML, Kessler LG. Use of gene tests to detect hereditary predisposition to cancer: What do we know about cost effectiveness? Int J Cancer 1996; 69: 55-7. http://dx. doi. org/10. 1002/(SICI) 1097-0215(19960220)69: 1<55:: AID-IJC14>3. 0. CO; 2-J.
23. Ramsey SD, Clarke L, Etzioni R, Higashi M, Berry K, Urban N. Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. Ann Intern Med 2001; 135: 577-88. http://dx. doi. org/10. 7326/0003-4819-135-8_Part_1-200110160-00008.
24. Hitchens MP, Ward RL. Constitutional (germline) MLH1 epimutation as an aetiological mechanism for hereditary non-polyposis colorectal cancer. Review. J Med Genet 2009; 46: 793-802. http://dx. doi. org/10. 1136/jmg. 2009. 068122.
25. Oliveira C, Westra J, Arango D, Ollikainen M, Domingo E, Ferreira A, et al. Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Hum Mol Genet 2004; 13: 2303-11. http://dx. doi. org/10. 1093/hmg/ddh238.
26. Zhang L. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing. J Mol Diag 2008; 10: 301-7. http://dx. doi. org/10. 2353/jmoldx. 2008. 080062.
27. Genetics Home Reference. What kinds of gene mutations are possible? In Help Me Understand Genetics. Bethesda, MD: US National Library of Medicine; 2013. pp. 43-8.
28. NHS Centre for Reviews and Dissemination. Undertaking Systematic Reviews of Research on Effectiveness. York: NHS Centre for Reviews and Dissemination, University of York; 2001.
29. Whiting PF, Westwood ME, Rutjes AW, Reitsma JB, Bossuyt PN, Kleijnen J. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol 2006; 6: 9. http://dx. doi. org/10. 1186/1471-2288-6-9.
30. Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, et al. Development of AMSTAR: A measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 2007; 7: 10. http://dx. doi. org/10. 1186/1471-2288-7-10.
31. Calistri D, Presciuttini S, Buonsanti G, Radice P, Gazzoli I, Pensotti V, et al. Microsatellite instability in colorectal-cancer patients with suspected genetic predisposition. Int J Cancer 2000; 89: 87-91. http://dx. doi. org/10. 1002/(SICI)1097-0215(20000120)89: 1<87:: AID-IJC14>3. 0. CO; 2-9.
32. Christensen M, Katballe N, Wikman F, Primdahl H, Sorensen FB, Laurberg S, et al. Antibody-based screening for hereditary nonpolyposis colorectal carcinoma compared with microsatellite analysis and sequencing. Cancer 2002; 95: 2422-30. http://dx. doi. org/10. 1002/cncr. 10979.
33. Katballe N, Christensen M, Wikman FP, Orntoft TF, Laurberg S. Frequency of hereditary non-polyposis colorectal cancer in Danish colorectal cancer patients. Gut 2002; 50: 43-51. http://dx. doi. org/10. 1136/gut. 50. 1. 43.
34. Debniak T, Kurzawski G, Gorski B, Kladny J, Domagala W, Lubinski J. Value of pedigree/clinical data, immunohistochemistry and microsatellite instability analyses in reducing the cost of determining hMLH1 and hMSH2 gene mutations in patients with colorectal cancer. Eur J Cancer 2000; 36: 49-54. http://dx. doi. org/10. 1016/S0959-8049(99)00208-7.
35. Dieumegard B, Grandjouan S, Sabourin JC, Le Bihan ML, Lefrère I, Bellefqih, et al. Extensive molecular screening for hereditary non-polyposis colorectal cancer. Br J Cancer 2000; 82: 871-80. http://dx. doi. org/10. 1054/bjoc. 1999. 1014.
36. Durno C, Aronson M, Bapat B, Cohen Z, Gallinger S. Family history and molecular features of children, adolescents, and young adults with colorectal carcinoma. Gut 2005; 54: 1146-50. http://dx. doi. org/10. 1136/gut. 2005. 066092.
37. Farrington SM, Lin-Goerke J, Ling J, Wang Y, Burczak JD, Robbins DJ, et al. Systematic analysis of hMSH2 and hMLH1 in young colon cancer patients and controls. Am J Hum Genet 1998; 63: 749-59. http://dx. doi. org/10. 1086/301996.
38. Peel DJ, Ziogas A, Fox EA, Gildea M, Laham B, Clements E, et al. Characterization of hereditary nonpolyposis colorectal cancer families from a population-based series of cases. J Natl Cancer Inst 2000; 92: 1517-22. http://dx. doi. org/10. 1093/jnci/92. 18. 1517.
39. Southey MC, Jenkins MA, Mead L, Whitty J, Trivett M, Tesoriero AA, et al. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer. J Clin Oncol 2005; 23: 6524-32. http://dx. doi. org/10. 1200/JCO. 2005. 04. 671.
40. Terdiman JP, Gum JR Jr, Conrad PG, Miller GA, Weinberg V, Crawley SC, et al. Efficient detection of hereditary nonpolyposis colorectal cancer gene carriers by screening for tumor microsatellite instability before germline genetic testing. Gastroenterology 2001; 120: 21-30. http://dx. doi. org/10. 1053/gast. 2001. 20874.
41. Wahlberg SS, Schmeits J, Thomas G, Loda M, Garber J, Syngal S, et al. Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families. Cancer Res 2002; 62: 3485-92.
42. Barrow E, Jagger E, Brierley J, Wallace A, Evans G, Hill J, et al. Semiquantitative assessment of immunohistochemistry for mismatch repair proteins in Lynch syndrome. Histopathology 2010; 56: 331-44. http://dx. doi. org/10. 1111/j. 1365-2559. 2010. 03485. x.
43. Becouarn Y, Rullier A, Gorry P, Smith D, Richard-Molard B, Echinard E, et al. Value of microsatellite instability typing in detecting hereditary non-polyposis colorectal cancer. A prospective multicentric study by the Association Aquitaine Gastro. Gastroenterol Clin Biol 2005; 29: 667-75. http://dx. doi. org/10. 1016/S0399-8320(05)82155-4.
44. Limburg PJ, Harmsen WS, Chen HH, Gallinger S, Haile RW, Baron JA, et al. Prevalence of alterations in DNA mismatch repair genes in patients with young-onset colorectal cancer. Clin Gastroenterol Hepatol 2011; 9: 497-502. http://dx. doi. org/10. 1016/j. cgh. 2010. 10. 021.
45. Stormorken AT, Bowitz-Lothe IM, Noren T, Kure E, Aase S, Wijnen J, et al. Immunohistochemistry identifies carriers of mismatch repair gene defects causing hereditary nonpolyposis colorectal cancer. J Clin Oncol 2005; 23: 4705-12. http://dx. doi. org/10. 1200/JCO. 2005. 05. 180.
46. Wolf B, Gruber S, Hengimueller S, Kappel S, Bergmann M, Wrba F, et al. Efficiency of the revised Bethesda guidelines (2003) for the detection of mutations in mismatch repair genes in Austrian HNPCC patients. Int J Cancer 2006; 118: 1465-70. http://dx. doi. org/10. 1002/ijc. 21524.
47. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996; 313: 275-83. http://dx. doi. org/10. 1136/bmj. 313. 7052. 275.
48. Ladabaum U, Wang G, Terdiman J, Blanco A, Kuppermann M, Boland CR, et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer. Ann Intern Med 2011; 155: 69-79. http://dx. doi. org/10. 7326/0003-4819-155-2-201107190-00002.
49. Ramsey SD, Burke W, Clarke L. An economic viewpoint on alternative strategies for identifying persons with hereditary nonpolyposis colorectal cancer. Genet Med 2003; 5: 353-63. http://dx. doi. org/10. 1097/01. GIM. 0000086626. 03082. B5.
50. Kievit W, De Bruin JHFM, Adang EMM, Severens JL, Kleibeuker JH, Sijmons RH, et al. Cost effectiveness of a new strategy to identify HNPCC patients. Gut 2005; 54: 97-102. http://dx. doi. org/10. 1136/gut. 2004. 039123.
51. Breheny N, Geelhoed E, Goldblatt J, Ee H, O'Leary P. Economic evaluation of the familial cancer programme in Western Australia: predictive genetic testing for familial adenomatous polyposis and hereditary non-polyposis colorectal carcinoma. Community Genet 2006; 9: 98-106. http://dx. doi. org/10. 1159/000091487.
52. Danish Centre for Evaluation and Health Technology Assessment. Hereditary Nonpolyposis Colorectal Cancer in Denmark-A Health Technology Assessment (Structured Abstract). Copenhagen: Danish Centre for Evaluation and Health Technology Assessment; 2007.
53. Olsen KR, Bojesen SE, Gerdes AM, Lindorff-Larsen K, Bernstein IT. Cost-effectiveness of surveillance programs for families at high and moderate risk of hereditary non-polyposis colorectal cancer. Int J Technol Assess Health Care 2007; 23: 89-95. http://dx. doi. org/10. 1017/S0266462307051616.
54. Mvundura M, Grosse SD, Hampel H, Palomaki GE. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med 2010; 12: 93-104. http://dx. doi. org/10. 1097/GIM. 0b013e3181cd666c.
55. Dinh TA, Rosner BI, Atwood JC, Boland CR, Syngal S, Vasen HFA, et al. Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res 2011; 4: 9-22. http://dx. doi. org/10. 1158/1940-6207. CAPR-10-0262.
56. Kwon JS, Scott JL, Gilks CB, Daniels MS, Sun CC, Lu KH. Testing women with endometrial cancer to detect Lynch syndrome. J Clin Oncol 2011; 29: 2247-52. http://dx. doi. org/10. 1200/JCO. 2010. 32. 9979.
57. Wang G, Kuppermann M, Kim B, Phillips KA, Ladabaum U. Influence of patient preferences on the cost-effectiveness of screening for Lynch syndrome. J Oncol Pract 2012; 8: e24s-30s. http://dx. doi. org/10. 1200/JOP. 2011. 000535.
58. Wang VW, Koh PK, Chow WL, Lim JFY. Predictive genetic testing of first degree relatives of mutation carriers is a cost-effective strategy in preventing hereditary nonpolyposis colorectal cancer in Singapore. Fam Cancer 2012; 11: 279-89. http://dx. doi. org/10. 1007/s10689-012-9513-y.
59. Reyes CM, Allen BA, Terdiman JP, Wilson LS. Comparison of selection strategies for genetic testing of patients with hereditary nonpolyposis colorectal carcinoma: effectiveness and cost-effectiveness. Cancer 2002; 95: 1848-56. http://dx. doi. org/10. 1002/cncr. 10910.
60. Pigatto F, Bateman A, Bunyan D, Strike P, Wilkins E, Curtis C, et al. Economic and practical factors in diagnosing HNPCC using clinical criteria, immunohistochemistry and microsatellite instability analysis. Hered Cancer Clin Pract 2004; 2: 175-84. http://dx. doi. org/10. 1186/1897-4287-2-4-175.
61. Pinol V, Castells A, Andreu M, Castellvi-Bel S, Alenda C, Llor X, et al. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. J Am Med Assoc 2005; 293: 1986-94. http://dx. doi. org/10. 1001/jama. 293. 16. 1986.
62. Engel C, Forberg J, Holinski-Feder E, Pagenstecher C, Plaschke J, Kloor M, et al. Novel strategy for optimal sequential application of clinical criteria, immunohistochemistry and microsatellite analysis in the diagnosis of hereditary nonpolyposis colorectal cancer. Int J Cancer 2006; 118: 115-22. http://dx. doi. org/10. 1002/ijc. 21313.
63. Bessa X, Balleste B, Andreu M, Castells A, Bellosillo B, Balaguer F, et al. A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening. Clin Gastroenterol Hepatol 2008; 6: 206-14. http://dx. doi. org/10. 1016/j. cgh. 2007. 10. 011.
64. Yan HL, Hao LQ, Jin HY, Xing QH, Xue G, Mei Q, et al. Clinical features and mismatch repair genes analyses of Chinese suspected hereditary non-polyposis colorectal cancer: a cost-effective screening strategy proposal. Cancer Sci 2008; 99: 770-80. http://dx. doi. org/10. 1111/j. 1349-7006. 2008. 00737. x.
65. Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 2009; 11: 42-65. http://dx. doi. org/10. 1097/GIM. 0b013e31818fa2db.
66. Ramsoekh D, van Leerdam ME, Wagner A, Kuipers EJ, Steyerberg EW. Mutation prediction models in Lynch syndrome: evaluation in a clinical genetic setting. J Med Genet 2009; 46: 745-51. http://dx. doi. org/10. 1136/jmg. 2009. 066589.
67. Resnick K, Straughn JM Jr, Backes F, Hampel H, Matthews KS, Cohn DE. Lynch syndrome screening strategies among newly diagnosed endometrial cancer patients. Obstet Gynecol 2009; 114: 530-6. http://dx. doi. org/10. 1097/AOG. 0b013e3181b11ecc.
68. Horwitz J, Geurts J, Einstein M, Qureshi J, Elramah M, Leo J, et al. The cost of detecting Lynch syndrome by microsatellite instability testing in community practice. Am J Gastroenterol 2010; 105: S547.
69. Gudgeon JM, Williams JL, Burt RW, Samowitz WS, Snow GL, Williams MS. Lynch syndrome screening implementation: business analysis by a healthcare system. Am J Manag Care 2011; 17: E288-300.
70. Perez-Carbonell L, Guarinus C, Soler MR, Sanchez-Fortun C, Sempere-Robles L, Ruiz-Ponte C, et al. Comparison between universal immunohistochemistry for mismatch repair proteins versus revised Bethesda guidelines in the detection of patients with Lynch syndrome. Gastroenterology 2011; 140(5 Suppl. 1): S97. http://dx. doi. org/10. 1016/S0016-5085(11)60394-6.
71. Williams MS, Gudgeon JM, Williams JL. Impact of age cutoffs on the efficiency of immunohistochemical tumor screening to identify Lynch syndrome. Familial cancer. Collaborative Group of the Americas on Inherited Colorectal Cancer conference, Montreal, QC, 10-11 October 2011. Conference publication 2011; 10: 731-2.
72. Gausachs M, Mur P, Corral J, Pineda M, Gonzalez S, Benito L, et al. MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study. Eur J Human Genet 2012; 20: 762-8. http://dx. doi. org/10. 1038/ejhg. 2011. 277.
73. Vasen HFA, Van Ballegooijen M, Buskens E, Kleibeuker JK, Taal BG, Griffioen G, et al. A cost-effectiveness analysis of colorectal screening of hereditary nonpolyposis colorectal carcinoma gene carriers. Cancer 1998; 82: 1632-7. http://dx. doi. org/10. 1002/(SICI)1097-0142 (19980501)82: 9<1632:: AID-CNCR6>3. 0. CO; 2-C.
74. Dunlop MG. Guidance on gastrointestinal surveillance for hereditary non-polyposis colorectal cancer, familial adenomatous polypolis, juvenile polyposis, and Peutz-Jeghers syndrome. Gut 2002; 51: 21-7. http://dx. doi. org/10. 1136/gut. 51. suppl_5. v21.
75. Kwon JS, Sun CC, Peterson SK, White KG, Daniels MS, Boyd-Rogers SG, et al. Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome. Cancer 2008; 113: 326-35. http://dx. doi. org/10. 1002/cncr. 23554.
76. Yang KY, Caughey AB, Little SE, Cheung MK, Chen LM. A cost-effectiveness analysis of prophylactic surgery versus gynecologic surveillance for women from hereditary non-polyposis colorectal cancer (HNPCC) families. Fam Cancer 2011; 10: 535-43. http://dx. doi. org/10. 1007/s10689-011-9444-z.
77. Rogowski W. Genetic screening by DNA technology: a systematic review of health economic evidence. Int J Technol Assess Health Care 2006; 22: 327-37. http://dx. doi. org/10. 1017/S0266462306051221.
78. Antonanzas F, Rodriguez-Ibeas R, Hutter M, Lorente R, Juarez C, Pinillos M. Genetic testing in the European Union: does economic evaluation matter? Eur J Health Econ 2012; 13: 651-61. http://dx. doi. org/10. 1007/s10198-011-0319-x.
79. Swedish Council on Technology Assessment in Health Care (SBU). Presymptomatic Diagnosis of Hereditary Colorectal Cancer-Early Assessment Briefs (ALERT) (Brief Record). Stockholm: SBU; 2001.
80. Phillips KA, Liang SY, Van Bebber S, Afable-Munsuz A, Knight SJ, Kuppermann M, et al. Challenges to the translation of genomic information into clinical practice and health policy: Utilization, preferences and economic value. Curr Opin Mol Ther 2008; 10: 260-6.
81. Barrow E, Alduaij W, Robinson L, Shenton A, Clancy T, Lalloo F, et al. Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations. Clin Genet 2008; 74: 233-42. http://dx. doi. org/10. 1111/j. 1399-0004. 2008. 01035. x.
82. Hagen A, Hessabi HK, Gorenoi V, Schonermark MP. [Cost-effectiveness evaluation of predictive molecular diagnostics using the example of hereditary non-polyposis colorectal cancer (HNPCC)]. Gesundheitswesen 2008; 70: 18-27. http://dx. doi. org/10. 1055/s-2007-1022526.
83. Syngal S, Weeks JC, Schrag D, Garber JE, Kuntz KM. Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations. Ann Intern Med 1998; 129: 787-96. http://dx. doi. org/10. 7326/0003-4819-129-10-199811150-00007.
84. Domingo E, Laiho P, Ollikainen M, Pinto M, Wang L, French AJ, et al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet 2004; 41: 664-8. http://dx. doi. org/10. 1136/jmg. 2004. 020651.
85. Chen LM, Yang KY, Little SE, Cheung MK, Caughey AB. Gynecologic cancer prevention in Lynch syndrome/hereditary nonpolyposis colorectal cancer families. Obstet Gynecol 2007; 110: 18-25. http://dx. doi. org/10. 1097/01. AOG. 0000267500. 27329. 85.
86. Maeda T, Cannom RR, Beart RW Jr, Etzioni DA. Decision model of segmental compared with total abdominal colectomy for colon cancer in hereditary nonpolyposis colorectal cancer. J Clin Oncol 2010; 28: 1175-80. http://dx. doi. org/10. 1200/JCO. 2009. 25. 9812.
87. De Vos Tot Nederveen Cappel WH, Buskens E, Van Duijvendijk P, Cats A, Menko FH, Griffioen G, et al. Decision analysis in the surgical treatment of colorectal cancer due to a mismatch repair gene defect. Gut 2003; 52: 1752-5. http://dx. doi. org/10. 1136/gut. 52. 12. 1752.
88. Brown ML, Kessler LG. The use of gene tests to detect hereditary predisposition to cancer: economic considerations. J Natl Cancer Inst 1995; 87: 1131-6. http://dx. doi. org/10. 1093/jnci/87. 15. 1131.
89. Surveillance, Epidemiology, and End Results (SEER) Program. Public-Use CD-ROM (1973-1997). Bethesda, MD: National Cancer Institute; 2000.
90. Ponz de Leon M. Descriptive epidemiology of hereditary non-polyposis colorectal cancer. Tumori 1996; 82: 102-6.
91. Lynch HT, Smyrk TC. Hereditary colorectal cancer. Semin Oncol 1999; 26: 478-84.
92. Vasen HF, Mecklin JP, Watson P, Utsunomiya J, Bertario L, Lynch P, et al. Surveillance in hereditary nonpolyposis colorectal cancer: an international cooperative study of 165 families. The International Collaborative Group on HNPCC. Dis Colon Rectum 1993; 36: 1-4. http://dx. doi. org/10. 1007/BF02050292.
93. Boland CR. Hereditary nonpolyposis colorectal cancer. In Vogelstein BK, Kinzler KW, editors. The Genetic Basis of Human Cancer. New York, NY: McGraw-Hill; 1998. pp. 333-46.
94. Jarvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomaki P, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000; 118: 829-34. http://dx. doi. org/10. 1016/S0016-5085(00)70168-5.
95. Australian lnstitute of Health and Welfare. Cancer in Australia 2000. Canberra: Australian Institute of Health and Welfare and Australasian Association of Cancer Registries; 2003.
96. Renkonen-Sinisalo L, Aarnio M, Mecklin JP, Jarvinen HJ. Surveillance improves survival of colorectal cancer in patients with hereditary nonpolyposis colorectal cancer. Cancer Detect Prev 2000; 24: 137-42.
97. Green J, O'Driscoll M, Barnes A, Maher ER, Bridge P, Shields K, et al. Impact of gender and parent of origin on the phenotypic expression of hereditary nonpolyposis colorectal cancer in a large Newfoundland kindred with a common MSH2 mutation. Dis Colon Rectum 2002; 45: 1223-32. http://dx. doi. org/10. 1007/s10350-004-6397-4.
98. National Institute for Health Technology Assessment. Cancer of the Colon and Rectum. Diagnosis and Screening. Copenhagen: Danish Institute for Health Technology Assessment; 2001.
99. Hendriks YM, Wagner A, Morreau H, Menko F, Stormorken A, Quehenberger F, et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology 2004; 127: 17-25. http://dx. doi. org/10. 1053/j. gastro. 2004. 03. 068.
100. Buttin BM, Powell MA, Mutch DG, Babb SA, Huettner PC, Edmonston TB, et al. Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history. Am J Hum Genet 2004; 74: 1262-9. http://dx. doi. org/10. 1086/421332.
101. Dunlop MG, Farrington SM, Carothers AD, Wyllie AH, Sharp L, Burn J, et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 1997; 6: 105-10. http://dx. doi. org/10. 1093/hmg/6. 1. 105.
102. Quehenberger F, Vasen HF, van Houwelingen HC. Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. J Med Genet 2005; 42: 491-6. http://dx. doi. org/10. 1136/jmg. 2004. 024299.
103. Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005; 352: 1851-60. http://dx. doi. org/10. 1056/NEJMoa043146.
104. Wagner A, Hendriks Y, Meijers-Heijboer EJ, de Leeuw WJ, Morreau H, Hofstra R, et al. Atypical HNPCC owing to MSH6 germline mutations: analysis of a large Dutch pedigree. J Med Genet 2001; 38: 318-22. http://dx. doi. org/10. 1136/jmg. 38. 5. 318.
105. Senter L, Clendenning M, Sotamaa K, Hampel H, Green J, Potter JD, et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 2008; 135: 419-28. http://dx. doi. org/10. 1053/j. gastro. 2008. 04. 026.
106. Stoffel E, Mukherjee B, Raymond VM, Tayob N, Kastrinos F, Sparr J, et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology 2009; 137: 1621-7. http://dx. doi. org/10. 1053/j. gastro. 2009. 07. 039.
107. Jarvinen HJ, Renkonen-Sinisalo L, Aktan-Collan K, Peltomaki P, Aaltonen LA, Mecklin J-P. Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol 2009; 27: 4793-7. http://dx. doi. org/10. 1200/JCO. 2009. 23. 7784.
108. Vasen HF, Abdirahman M, Brohet R, Langers AM, Kleibeuker JH, van Kouwen M, et al. One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. Gastroenterology 2010; 138: 2300-6. http://dx. doi. org/10. 1053/j. gastro. 2010. 02. 053.
109. de Jong AE, Hendriks YM, Kleibeuker JH, de Boer SY, Cats A, Griffioen G, et al. Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology 2006; 130: 665-71. http://dx. doi. org/10. 1053/j. gastro. 2005. 11. 032.
110. Cotterchio M, Manno M, Klar N, McLaughlin J, Gallinger S. Colorectal screening is associated with reduced colorectal cancer risk: a case-control study within the population-based Ontario Familial Colorectal Cancer Registry. Cancer Causes Control 2005; 16: 865-75. http://dx. doi. org/10. 1007/s10552-005-2370-3.
111. Boursi B, Halak A, Umansky M, Galzan L, Guzner-Gur H, Arber N. Colonoscopic screening of an average-risk population for colorectal neoplasia. Endoscopy 2009; 41: 516-21. http://dx. doi. org/10. 1055/s-0029-1214757.
112. Rundle AG, Lebwohl B, Vogel R, Levine S, Neugut AI. Colonoscopic screening in average-risk individuals ages 40 to 49 vs 50 to 59 years. Gastroenterology 2008; 134: 1311-15. http://dx. doi. org/10. 1053/j. gastro. 2008. 02. 032.
113. Altekruse SF, Kosary CL, Krapcho M, Neyman M, Aminou R, Waldron W, et al. Lifetime Risk, SEER Cancer Statistics Review, 1975-2007. National Cancer Institute. Bethesda, MD. URL: http://seer. cancer. gov/archive/csr/1975_2007/results_merged/topiclifetimerisk. pdf (accessed August 2014).
114. Jenkins MA, Baglietto L, Dowty JG, Van Vliet CM, Smith L, Mead LJ, et al. Cancer risks for mismatch repair gene mutation carriers: a population-based early onset case-family study. Clin Gastroenterol Hepatol 2006; 4: 489-98. http://dx. doi. org/10. 1016/j. cgh. 2006. 01. 002.
115. Altekruse SF, Kosary CL, Krapcho M, Neyman M, Waldron W, et al. SEER Cancer Statistics Review 1975-2007. Bethesda, MD: National Cancer Institute; 2010. URL: http://seer. cancer. gov/csr/1975_2007/(accessed August 2011).
116. Vasen HF, Wijnen JT, Menko FH, Kleibeuker JH, Taal BG, Griffioen G, et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996; 110: 1020-7. http://dx. doi. org/10. 1053/gast. 1996. v110. pm8612988.
117. Vasen HF, Taal BG, Nagengast FM, Griffioen G, Menko FH, Kleibeuker JH, et al. Hereditary nonpolyposis colorectal cancer: results of long-term surveillance in 50 families. Eur J Cancer 1995; 31A: 1145-8. http://dx. doi. org/10. 1016/0959-8049(95)00249-I.
118. Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999; 81: 214-18. http://dx. doi. org/10. 1002/(SICI)1097-0215(19990412)81: 2<214:: AID-IJC8>3. 0. CO; 2-L.
119. Office for National Statistics. Cancer Statistics Registrations, England (Series MB1)-No. 41, 2010. 2012. URL: www. ons. gov. uk/ons/rel/vsob1/cancer-statistics-registrations-england-series-mb1-/no-41-2010/index. html (accessed July 2014).
120. Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clinical Oncol 2008; 26: 5783-8. http://dx. doi. org/10. 1200/JCO. 2008. 17. 5950.
121. Barrow E, Robinson L, Alduaij W, Shenton A, Clancy T, Lalloo F, et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet 2009; 75: 141-9. http://dx. doi. org/10. 1111/j. 1399-0004. 2008. 01125. x.
122. Oxford Medical Genetics Laboratories. Current Disease Services. Oxford: Oxford University Hospitals NHS Trust; 2011. URL: www. oxfordradcliffe. nhs. uk/forclinicians/referrals/genetics/medical_genetics/documents/diseaseservices. pdf (accessed August 2012).
123. John M. AWMGL Service Price List. Cardiff: All Wales Molecular Genetics Laboratory; 2012. URL: www. wales. nhs. uk/sites3/Documents/525/MI-MGN-TestPrice_5. 1. pdf (accessed August 2012).
124. East of Scotland Regional Genetics Service. Molecular Genetics List of Disorders. Dundee: East of Scotland Regional Genetics Service; 2012. URL: http://134. 36. 196. 124/Molecular_Genetics_List_of_Disorders. htm (accessed August 2012).
125. East Anglian Medical Genetics Laboratories. Services and Tests Available. Cambridge: Cambridge University Hospitals NHS Foundation Trust; 2012. URL: www. cuh. org. uk/addenbrookes/services/clinical/genetics/genetics_labs/services_test/services_test_index. html (accessed August 2012).
126. Yorkshire Regional Genetics Service. Hereditary Nonpolyposis Colorectal Cancer (HNPCC). Leeds: Leeds Teaching Hospitals; 2012.
127. Hall G, Clarkson A, Shi A, Langford E, Leung H, Eckstein RP, et al. Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma. Pathology 2010; 42: 409-13. http://dx. doi. org/10. 3109/00313025. 2010. 493871.
128. Klarskov L, Ladelund S, Holck S, Roenlund K, Lindebjerg J, Elebro J, et al. Interobserver variability in the evaluation of mismatch repair protein immunostaining. Human Pathol 2010; 41: 1387-96. http://dx. doi. org/10. 1016/j. humpath. 2010. 03. 003.
129. Barton P, Bryan S, Robinson S. Modelling in the economic evaluation of health care: selecting the appropriate approach. J Health Serv Res Pol 2004; 9: 110-18. http://dx. doi. org/10. 1258/135581904322987535.
130. Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ 2006; 15: 1295-310. http://dx. doi. org/10. 1002/hec. 1148.
131. American Joint Committee on Cancer. Cancer Staging Manual. 7th edn. New York, NY: Springer; 2010.
132. National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal. London: National Institute for Health and Care Excellence; 2013.
133. National Institute for Health and Care Excellence. Colorectal Cancer: The Diagnosis and Management of Colorectal Cancer. London: National Institute for Health and Care Excellence; 2011.
134. Trueman P, Lowson K, Bending M, Ganderton M, Chaplin S, Wright D, et al. Bowel Cancer Services: Costs and Benefits. York: York Health Economics Consortium; 2007.
135. Finan P, Smith J, Walker K, van der Meulen J, Greenaway K, Yelland A, et al. National Bowel Cancer Audit Annual Report. Leeds: NHS Information Centre for Health and Social Care; 2011.
136. Office for National Statistics. Cancer Statistics Registrations, England (Series MB1)-No. 37, 2006. 2008. URL: www. ons. gov. uk/ons/rel/vsob1/cancer-statistics-registrations-england-series-mb1-/no-37-2006/index. html (accessed July 2014).
137. Office for National Statistics. Cancer Statistics Registrations, England (Series MB1)-No. 39, 2008. 2010. URL: www. ons. gov. uk/ons/rel/vsob1/cancer-statistics-registrations-england-series-mb1-/no-39-2008/index. html (accessed July 2014).
138. Office for National Statistics. Cancer Statistics Registrations, England (Series MB1)-No. 38, 2007. 2010. URL: www. ons. gov. uk/ons/rel/vsob1/cancer-statistics-registrations-england-series-mb1-/no-38-2007/index. html (accessed July 2014).
139. Office for National Statistics. Cancer Statistics Registrations, England (Series MB1)-No. 40, 2009. 2011. URL: www. ons. gov. uk/ons/rel/vsob1/cancer-statistics-registrations-england-series-mb1-/no-40-2009/index. html (accessed July 2014).
140. Office for National Statistics. Mid-2010 Population Estimates: England and Wales; Estimated Resident Population by Single Year of Age and Sex. 2011. URL: www. ons. gov. uk/ons/rel/pop-estimate/population-estimates-for-uk-england-and-wales-scotland-and-northern-ireland/mid-2010-population-estimates/rft-mid-2010-population-estimates. zip (accessed July 2014).
141. Office for National Statistics. Mid-2002 to Mid-2010 Population Estimates of the Very Elderly (Including Centenarians) England and Wales; Estimated Resident Population. 2011. URL: www. ons. gov. uk/ons/rel/mortality-ageing/population-estimates-of-the-very-elderly/2010/ew-eve-2010. xls (accessed July 2014).
142. National Cancer Intelligence Network. One, Five and Ten Year Cancer Prevalence by Cancer Network, UK, 2006. 2010. URL: www. ncin. org. uk/view. aspx?rid=76 (accessed July 2014).
143. Office for National Statistics. Mortality Statistics: Deaths Registered in 2010 (Series DR). 2011. URL: www. ons. gov. uk/ons/rel/vsob1/mortality-statistics-deaths-registered-in-england-and-wales-series-dr-/2010/dr-tables-2010. xls (accessed July 2014).
144. Office for National Statistics. Mid-1971 to Mid-2010 Population Estimates: Quinary Age Groups for Constituent Countries in the United Kingdom; Estimated Resident Population. 2011. URL: www. ons. gov. uk/ons/rel/pop-estimate/population-estimates-for-uk-england-and-wales-scotland-and-northern-ireland/population-estimates-timeseries-1971-to-current-year/rft-table-2-quinary-age-groups-constituent-countries. zip (accessed July 2014).
145. Welsh Cancer Intelligence and Surveillance Unit. Cancer Incidence in Wales 2006-2010. 2012. URL: www. wcisu. wales. nhs. uk/opendoc/226155 (accessed July 2014).
146. Schmeler KM, Lynch HT, Chen LM, Munsell MF, Soliman PT, Clark MB, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. New Engl J Med 2006; 354: 261-9. http://dx. doi. org/10. 1056/NEJMoa052627.
147. Office for National Statistics. Cancer Survival in England-Patients Diagnosed 2006-2010 and Followed Up to 2011. 2012. URL: www. ons. gov. uk/ons/publications/re-reference-tables. html? edition=tcm%3A77-277733 (accessed July 2014).
148. Office for National Statistics. Cancer Survival in England-Patients Diagnosed 2005-2009 and Followed Up to 2010. 2011. URL: www. ons. gov. uk/ons/publications/re-reference-tables. html? edition=tcm%3A77-239726 (accessed July 2014).
149. National Cancer Intelligence Network (NCIN), UK Cancer Information Service (UKCIS). UK Cancer e-Atlas. 2011. URL: www. ncin. org. uk/cancer_information_tools/eatlas/pct/atlas. html?select=Eav& indicator=i0 (accessed July 2014).
150. Cancer Research UK. Uterine Cancer Survival Statistics. London: Cancer Research UK; 2012. URL: www. cancerresearchuk. org/cancer-info/cancerstats/types/uterus/survival/(accessed December 2012).
151. Department of Health. NHS Reference Costs 2011-2012. London: Department of Health; 2012. URL: www. dh. gov. uk/health/2012/11/2011-12-reference-costs/(accessed March 2013).
152. Havrilesky L, Maxwell G, Myers E. Cost-effectiveness analysis of annual screening strategies for endometrial cancer. Am J Obstet Gynecol 2009; 200: 640. e1-8. http://dx. doi. org/10. 1016/j. ajog. 2009. 02. 022.
153. Commercial Medicines Unit. Electronic Market Information Tool (eMit). 2013. URL: http://cmu. dh. gov. uk/electronic-market-information-tool-emit (accessed July 2014).
154. Department of Health. NHS Reference Costs 2008-9. London: Department of Health; 2010. URL: www. dh. gov. uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_111591 (accessed July 2014).
155. National Institute for Health and Care Excellence. Laparoscopic Hysterectomy (Including Laparoscopic Total Hysterectomy and Laparoscopically Assisted Vaginal Hysterectomy) for Endometrial Cancer: Guidance. 2010. URL: www. nice. org. uk/guidance/IPG356/Guidance/pdf (accessed July 2014).
156. NHS. Treating Uterine (Uterus) Cancer. 2013. URL: www. nhs. uk/conditions/Cancer-of-the-uterus/Pages/treatment. aspx (accessed July 2014).
157. Baker M, Kessler L, Smucker R. Site-specific treatment costs for cancer: an analysis of the Medicare continuous history sample file. In Scheffler RM, Andrews NC, Phillips KA, American Cancer Society (California Division), editors. Cancer Care and Cost: DRGs and Beyond. Ann Arbor, MI: Health Administration Press; 1989. pp. 127-38.
158. National Insitute for Health and Care Excellence. Published Clinical Guidelines. 2013. URL: http://guidance. nice. org. uk/CG/Published (accessed July 2014).
159. Macmillan Cancer Support. Radiotherapy for Womb Cancer (Endometrial Cancer). 2013. URL: www. macmillan. org. uk/Cancerinformation/Cancertypes/Wombuterus/Treatingwombcancer/Radiotherapy. asp (accessed January 2013).
160. Markman M. Chemotherapy in the management of endometrial cancer. J Gynecol Oncol 2007; 12: 29-32.
161. Mulder SA, Kranse R, Damhuis RA, Ouwendijk RJ, Kuipers EJ, van Leerdam ME. The incidence and risk factors of metachronous colorectal cancer: an indication for follow-up. Dis Colon Rectum 2012; 55: 522-31. http://dx. doi. org/10. 1097/DCR. 0b013e318249db00.
162. Carayol J, Bonaiti-Pellie C. Estimating penetrance from family data using a retrospective likelihood when ascertainment depends on genotype and age of onset. Genet Epidemiol 2004; 27: 109-17. http://dx. doi. org/10. 1002/gepi. 20007.
163. Rasmussen LJ, Heinen CD, Royer-Pokora B, Drost M, Tavtigian S, Hofstra RM, et al. Pathological assessment of mismatch repair gene variants in Lynch syndrome: past, present, and future. Hum Mutat 2012; 33: 1617-25. http://dx. doi. org/10. 1002/humu. 22168.
164. van Vliet CM, Dowty JG, van Vliet JL, Smith L, Mead LJ, Macrae FA, et al. Dependence of colorectal cancer risk on the parent-of-origin of mutations in DNA mismatch repair genes. Hum Mutat 2011; 32: 207-12. http://dx. doi. org/10. 1002/humu. 21408.
165. Alarcon F, Lasset C, Carayol J, Bonadona V, Perdry H, Desseigne F, et al. Estimating cancer risk in HNPCC by the GRL method. Eur J Hum Genet 2007; 15: 831-6. http://dx. doi. org/10. 1038/sj. ejhg. 5201843.
166. Baglietto L, Lindor NM, Dowty JG, White DM, Wagner A, Gomez Garcia EB, et al. Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst 2010; 102: 193-201. http://dx. doi. org/10. 1093/jnci/djp473.
167. Lindor NM, Petersen GM, Hadley DW, Kinney AY, Miesfeldt S, Lu KH, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome-A systematic review. JAMA 2006; 296: 1507-17. http://dx. doi. org/10. 1001/jama. 296. 12. 1507.
168. Parry S, Win AK, Parry B, Macrae FA, Gurrin LC, Church JM, et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut 2011; 60: 950-7. http://dx. doi. org/10. 1136/gut. 2010. 228056.
169. Fajobi O, Yiu CY, Sen-Gupta SB, Boulos PB. Metachronous colorectal cancers. Br J Surg 1998; 85: 897-901. http://dx. doi. org/10. 1046/j. 1365-2168. 1998. 00800. x.
170. National Cancer Intelligence Network. Colorectal Cancer Survival by Stage. 2009. URL: www. ncin. org. uk/publications/data_briefings/colorectal_cancer_survival_by_stage. aspx (accessed July 2014).
171. Cancer Research UK. Bowel Cancer Survival Statistics. 2013. URL: www. cancerresearchuk. org/cancer-info/cancerstats/types/bowel/survival (accessed July 2014).
172. Coate L, Cuffe S, Horgan A, Hung RJ, Christiani D, Liu G. Germline genetic variation, cancer outcome, and pharmacogenetics. J Clin Oncol 2010; 28: 4029-37. http://dx. doi. org/10. 1200/JCO. 2009. 27. 2336.
173. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005; 23: 609-18. http://dx. doi. org/10. 1200/JCO. 2005. 01. 086.
174. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010; 138: 2073-87. e3.
175. Barnetson RA, Tenesa A, Farrington SM, Nicholl ID, Cetnarskyj R, Porteous ME, et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med 2006; 354: 2751-63. http://dx. doi. org/10. 1056/NEJMoa053493.
176. Lin KM, Shashidharan M, Ternent CA, Thorson AG, Blatchford GJ, Christensen MA, et al. Colorectal and extracolonic cancer variations in MLH1/MSH2 hereditary nonpolyposis colorectal cancer kindreds and the general population. Dis Colon Rectum 1998; 41: 428-33. http://dx. doi. org/10. 1007/BF02235755.
177. Horner M, Ries L, Krapcho M, Neyman N, Aminou R, Howlader N, et al. SEER Cancer Statistics Review, 1975-2006. Bethesda, MD: National Cancer Institute; 2009. URL: http://seer. cancer. gov/csr/1975_2006 (accessed July 2014).
178. Boks DE, Trujillo AP, Voogd AC, Morreau H, Kenter GG, Vasen HF. Survival analysis of endometrial carcinoma associated with hereditary nonpolyposis colorectal cancer. Int J Cancer 2002; 102: 198-200. http://dx. doi. org/10. 1002/ijc. 10667.
179. Office for National Statistics. England and Wales, Interim Life Tables, 1980-82 to 2008-10. 2011. URL: www. ons. gov. uk/ons/rel/lifetables/interim-life-tables/2008-2010/rft-ilt-ew-2008-2010. xls (accessed July 2014).
180. Salovaara R, Loukola A, Kristo P, Kaariainen H, Ahtola H, Eskelinen M, et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol 2000; 18: 2193-200.
181. Green RC, Parfrey PS, Woods MO, Younghusband HB. Prediction of Lynch syndrome in consecutive patients with colorectal cancer. J Natl Cancer Inst 2009; 101: 331-40. http://dx. doi. org/10. 1093/jnci/djn499.
182. Balmana J, Balaguer F, Castellvi-Bel S, Steyerberg EW, Andreu M, Llor X, et al. Comparison of predictive models, clinical criteria and molecular tumour screening for the identification of patients with Lynch syndrome in a population-based cohort of colorectal cancer patients. J Med Genet 2008; 45: 557-63. http://dx. doi. org/10. 1136/jmg. 2008. 059311.
183. Domingo E, Niessen RC, Oliveira C, Alhopuro P, Moutinho C, Espin E, et al. BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene 2005; 24: 3995-8. http://dx. doi. org/10. 1038/sj. onc. 1208569.
184. Sjursen W, Haukanes BI, Grindedal EM, Aarset H, Stormorken A, Engebretsen LF, et al. Current clinical criteria for Lynch syndrome are not sensitive enough to identify MSH6 mutation carriers. J Med Genet 2010; 47: 579-85. http://dx. doi. org/10. 1136/jmg. 2010. 077677.
185. Jenkins MA, Baglietto L, Dite GS, Jolley DJ, Southey MC, Whitty J, et al. After hMSH2 and hMLH1-what next? Analysis of three-generational, population-based, early-onset colorectal cancer families. Int J Cancer 2002; 102: 166-71. http://dx. doi. org/10. 1002/ijc. 10670.
186. Win AK, Parry S, Parry B, Kalady MF, Macrae FA, Ahnen DJ, et al. Risk of metachronous colon cancer following surgery for rectal cancer in mismatch repair gene mutation carriers. Ann Surg Oncol 2013; 20: 1829-36. http://dx. doi. org/10. 1245/s10434-012-2858-5.
187. Cirillo L, Urso ED, Parrinello G, Pucciarelli S, Moneghini D, Agostini M, et al. High risk of rectal cancer and of metachronous colorectal cancer in probands of families fulfilling the Amsterdam Criteria. Ann Surg 2012; 257: 900-4. http://dx. doi. org/10. 1097/SLA. 0b013e31826bff79.
188. Mecklin JP, Aarnio M, Laara E, Kairaluoma MV, Pylvanainen K, Peltomaki P, et al. Development of colorectal tumors in colonoscopic surveillance in Lynch syndrome. Gastroenterology 2007; 133: 1093-8. http://dx. doi. org/10. 1053/j. gastro. 2007. 08. 019.
189. Gavin DR, Valori RM, Anderson JT, Donnelly MT, Williams JG, Swarbrick ET. The national colonoscopy audit: a nationwide assessment of the quality and safety of colonoscopy in the UK. Gut 2013; 62: 242-9. http://dx. doi. org/10. 1136/gutjnl-2011-301848.
190. Dove-Edwin I, Boks D, Goff S, Kenter GG, Carpenter R, Vasen HFA, et al. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer 2002; 94: 1708-12. http://dx. doi. org/10. 1002/cncr. 10380.
191. Renkonen-Sinisalo L, Butzow R, Leminen A, Lehtovirta P, Mecklin J-P, Jarvinen HJ. Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. Int J Cancer 2007; 120: 821-4. http://dx. doi. org/10. 1002/ijc. 22446.
192. Auranen A, Joutsiniemi T. A systematic review of gynecological cancer surveillance in women belonging to hereditary nonpolyposis colorectal cancer (Lynch syndrome) families. Acta Obstet Gynecol Scand 2011; 90: 437-44. http://dx. doi. org/10. 1111/j. 1600-0412. 2011. 01091. x.
193. Koornstra JJ, Mourits MJ, Sijmons RH, Leliveld AM, Hollema H, Kleibeuker JH. Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol 2009; 10: 400-8. http://dx. doi. org/10. 1016/S1470-2045(09)70041-5.
194. Gerritzen LHM, Hoogerbrugge N, Oei ALM, Nagengast FM, van Ham MAPC, Massuger LFAG, et al. Improvement of endometrial biopsy over transvaginal ultrasound alone for endometrial surveillance in women with Lynch syndrome. Fam Cancer 2009; 8: 391-7. http://dx. doi. org/10. 1007/s10689-009-9252-x.
195. Lécuru F, Le Frere Belda MA, Bats AS, Tulpin L, Metzger U, Olschwang S, et al. Performance of office hysteroscopy and endometrial biopsy for detecting endometrial disease in women at risk of human non-polyposis colon cancer: a prospective study. Int J Gynecol Cancer 2008; 18: 1326-31. http://dx. doi. org/10. 1111/j. 1525-1438. 2007. 01183. x.
196. Rijcken FEM, Mourits MJE, Kleibeuker JH, Hollema H, van der Zee AGJ. Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 2003; 91: 74-80. http://dx. doi. org/10. 1016/S0090-8258(03)00371-8.
197. Papaioannou D, Brazier J, Paisley S. NICE DSU Technical Support Document 9: The Identification, Review and Synthesis of Health State Utility Values from the Literature. Sheffield: School of Health and Related Research, University of Sheffield; 2010. URL: www. nicedsu. org. uk/TSD9%20HSUV% 20values_FINAL. pdf (accessed July 2014).
198. National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal. London: National Institute for Health and Care Excellence; 2008.
199. Gritz ER, Peterson SK, Vernon SW, Marani SK, Baile WF, Watts BG, et al. Psychological impact of genetic testing for hereditary nonpolyposis colorectal cancer. J Clin Oncol 2005; 23: 1902-10. http://dx. doi. org/10. 1200/JCO. 2005. 07. 102.
200. Ness RM, Holmes AM, Klein R, Dittus R. Utility valuations for outcome states of colorectal cancer. Am J Gastroenterol 1999; 94: 1650-7. http://dx. doi. org/10. 1111/j. 1572-0241. 1999. 01157. x.
201. van Duijvendijk P, Slors JFM, Taat CW, Oosterveld P, Sprangers MAG, Obertop H, et al. Quality of life after total colectomy with ileorectal anastomosis or proctocolectomy and ileal pouch-anal anastomosis for familial adenomatous polyposis. Br J Surg 2000; 87: 590-6. http://dx. doi. org/10. 1046/j. 1365-2168. 2000. 01442. x.
202. Fazio VW, O'Riordain MG, Lavery IC, Church JM, Lau P, Strong SA, et al. Long-term functional outcome and quality of life after stapled restorative proctocolectomy. Ann Surg 1999; 230: 575-84. http://dx. doi. org/10. 1097/00000658-199910000-00013.
203. Carter KJ, Ritchey NP, Castro F, Caccamo LP, Kessler E, Erickson BA, et al. Treatment of early-stage breast cancer in the elderly: a health-outcome-based approach. Med Decis Making 1998; 18: 213-19.
204. Grann VR, Sundararajan V, Jacobson JS, Whang W, Heitjan DF, Antman KH, et al. Decision analysis of tamoxifen for the prevention of invasive breast cancer. Cancer J 2000; 6: 169-78.
205. Hillner BE, Hollenberg JP, Pauker SG. Postmenopausal estrogens in prevention of osteoporosis. Benefit virtually without risk if cardiovascular effects are considered. Am J Med 1986; 80: 1115-27. http://dx. doi. org/10. 1016/0002-9343(86)90674-1.
206. Weinstein MC, Schiff I. Cost-effectiveness of hormone replacement therapy in the menopause. Obstet Gynecol Surv 1983; 38: 445-55. http://dx. doi. org/10. 1097/00006254-198308000-00001.
207. Sun CC, Peterson SK, White KG, Watts BG, Daniels MS, Boyd-Rogers SG, et al. Preferences for cancer prevention strategies (CPS) in women with hereditary nonpolyposis colorectal cancer (HNPCC). ASCO Meeting Abstracts 2006; 24: 1018.
208. Grann VR, Jacobson JS, Thomason D, Hershman D, Heitjan DF, Neugut AI. Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA12 mutations: an updated decision analysis. J Clin Oncol 2002; 20: 2520-9. http://dx. doi. org/10. 1200/JCO. 2002. 10. 101.
209. Grann VR, Panageas KS, Whang W, Antman KH, Neugut AI. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J Clin Oncol 1998; 16: 979-85.
210. Ortega A, Dranitsaris G, Sturgeon J, Sutherland H, Oza A. Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer. Gynecol Oncol 1997; 66: 454-63. http://dx. doi. org/10. 1006/gyno. 1997. 4786.
211. van Roosmalen MS, Verhoef LCG, Stalmeier PFM, Hoogerbrugge N, van Daal WAJ. Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy. J Clin Oncol 2002; 20: 2092-100. http://dx. doi. org/10. 1200/JCO. 2002. 08. 035.
212. Kuppermann M, Wang G, Wong S, Blanco A, Conrad P, Nakagawa S, et al. Preferences for outcomes associated with decisions to undergo or forgo genetic testing for Lynch syndrome. Cancer 2013; 119: 215-25. http://dx. doi. org/10. 1002/cncr. 27634.
213. Cooper K, Squires H, Carroll C, Papaioannou D, Booth A, Logan R, et al. Chemoprevention of colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2010; 14(32).
214. Whyte S, Chilcott J, Halloran S. Reappraisal of the options for colorectal cancer screening in England. Colorectal Dis 2012; 14: e547-61. http://dx. doi. org/10. 1111/j. 1463-1318. 2012. 03014. x.
215. Ara R, Brazier JE. Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available. Value Health 2011; 14: 539-45.
216. Ara R, Brazier JE. Populating an economic model with health state utility values: moving towards better practice. Value Health 2010; 13: 509-18. http://dx. doi. org/10. 1111/j. 1524-4733. 2010. 00700. x.
217. Ramsey SD, Andersen MR, Etzioni R, Moinpour C, Peacock S, Potosky A, et al. Quality of life in survivors of colorectal carcinoma. Cancer 2000; 88: 1294-303. http://dx. doi. org/10. 1002/(SICI)1097-0142(20000315)88: 6<1294:: AID-CNCR4>3. 0. CO; 2-M.
218. Ramsey SD, Berry K, Moinpour C, Giedzinska A, Andersen MR. Quality of life in long term survivors of colorectal cancer. Am J Gastroenterol 2002; 97: 1228-34. http://dx. doi. org/10. 1111/j. 1572-0241. 2002. 05694. x.
219. Ko CY, Maggard M, Livingston EH. Evaluating health utility in patients with melanoma, breast cancer, colon cancer, and lung cancer: a nationwide, population-based assessment. J Surg Res 2003; 114: 1-5. http://dx. doi. org/10. 1016/S0022-4804(03)00167-7.
220. Petrou S, Campbell N. Stabilisation in colorectal cancer. Int J Pall Nurs 1997; 3: 275-80.
221. Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007; 370: 143-52. http://dx. doi. org/10. 1016/S0140-6736(07)61087-3.
222. Wilke H, Glynne-Jones R, Thaler J, Adenis A, Preusser P, Aguilar EA, et al. Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL study. J Clin Oncol 2008; 26: 5335-43. http://dx. doi. org/10. 1200/JCO. 2008. 16. 3758.
223. Starling N, Tilden D, White J, Cunningham D. Cost-effectiveness analysis of cetuximab/irinotecan vs. active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment. Br J Cancer 2007; 96: 206-12. http://dx. doi. org/10. 1038/sj. bjc. 6603561.
224. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu DS, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040-8. http://dx. doi. org/10. 1056/NEJMoa071834.
225. Mittmann N, Au HJ, Tu DS, O'Callaghan CJ, Isogai PK, Karapetis CS, et al. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO. 17 trial. J Nat Cancer Inst 2009; 101: 1182-92. http://dx. doi. org/10. 1093/jnci/djp232.
226. Best JH, Garrison LP, Hollingworth W, Ramsey SD, Veenstra DL. Preference values associated with stage III colon cancer and adjuvant chemotherapy. Qual Life Res 2010; 19: 391-400. http://dx. doi. org/10. 1007/s11136-010-9589-5.
227. Kalady M, Dziedzic M, Manilich E, Lynch C, McGannon E, Fay S, et al. Quality of life after surgery for colorectal cancer in HNPCC patients. Fam Cancer 2011; 10: 718.
228. Ara R, Brazier J. Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available). Value Health 2008; 11: 1131-43. http://dx. doi. org/10. 1111/j. 1524-4733. 2008. 00352. x.
229. Bye A, Trope C, Loge JH, Hjermstad M, Kaasa S. Health-related quality of life and occurrence of intestinal side effects after pelvic radiotherapy-Evaluation of long-term effects of diagnosis and treatment. Acta Oncol 2000; 39: 173-80. http://dx. doi. org/10. 1080/028418600430734.
230. De Poll-Franse LVV, Mols F, Essink-Bot ML, Haartsen JE, Vingerhoets JJM, Lybeert MLM, et al. Impact of external beam adjuvant radiotherapy on health-related quality of life for long-term survivors of endometrial adenocarcinoma: a population-based study. Int J Radiat Oncol Biol Physics 2007; 69: 125-32. http://dx. doi. org/10. 1016/j. ijrobp. 2007. 02. 040.
231. NHS. Hysterectomy. 2013. URL: www. nhs. uk/Conditions/Hysterectomy/Pages/Introduction. aspx (accessed July 2014).
232. Collins VR, Meiser B, Ukoumunne OC, Gaff C, John DJS, Halliday JL. The impact of predictive genetic testing for hereditary nonpolyposis colorectal cancer: three years after testing. Genet Med 2007; 9: 290-7. http://dx. doi. org/10. 1097/GIM. 0b013e31804b45db.
233. Aktan-Collan K, Haukkala A, Mecklin JP, Uutela A, Kaariainen H. Psychological consequences of predictive genetic testing for hereditary non-polyposis colorectal cancer (HNPCC): a prospective follow-up study. Int J Cancer 2001; 93: 608-11. http://dx. doi. org/10. 1002/ijc. 1372.
234. Shiloh S, Koehly L, Jenkins J, Martin J, Hadley D. Monitoring coping style moderates emotional reactions to genetic testing for hereditary nonpolyposis colorectal cancer: a longitudinal study. Psychooncology 2008; 17: 746-55. http://dx. doi. org/10. 1002/pon. 1338.
235. Claes E, Evers-Kiebooms G, Decruyenaere M, Denayer L, Boogaerts A, Philippe K, et al. Surveillance behavior and prophylactic surgery after predictive testing for hereditary breast/ovarian cancer. Behav Med 2005; 31: 93-105. http://dx. doi. org/10. 3200/BMED. 31. 3. 93-106.
236. Keller M, Jost R, Haunstetter CM, Sattel H, Schroeter C, Bertsch U, et al. Psychosocial outcome following genetic risk counselling for familial colorectal cancer. A comparison of affected patients and family members. Clin Genet 2008; 74: 414-24. http://dx. doi. org/10. 1111/j. 1399-0004. 2008. 01089. x.
237. Meiser B, Collins V, Warren R, Gaff C, St John DJ, Young MA, et al. Psychological impact of genetic testing for hereditary non-polyposis colorectal cancer. Clin Genet 2004; 66: 502-11. http://dx. doi. org/10. 1111/j. 1399-0004. 2004. 00339. x.
238. Hasenbring MI, Kreddig N, Deges G, Epplen JT, Kunstmann E, Stemmler S, et al. Psychological impact of genetic counseling for hereditary nonpolyposis colorectal cancer: the role of cancer history, gender, age, and psychological distress. Genet Test Mol Biomarkers 2011; 15: 219-25. http://dx. doi. org/10. 1089/gtmb. 2010. 0165.
239. Heshka JT, Palleschi C, Howley H, Wilson B, Wells PS. A systematic review of perceived risks, psychological and behavioral impacts of genetic testing. Genet Med 2008; 10: 19-32. http://dx. doi. org/10. 1097/GIM. 0b013e31815f524f.
240. van Oostrom I, Meijers-Heijboer H, Duivenvoorden HJ, Brocker-Vriends A, van Asperen CJ, Sijmons RH, et al. Comparison of individuals opting for BRCA1/2 or HNPCC genetic susceptibility testing with regard to coping, illness perceptions, illness experiences, family system characteristics and hereditary cancer distress. Patient Educ Counsel 2007; 65: 58-68. http://dx. doi. org/10. 1016/j. pec. 2006. 05. 006.
241. Bleiker EMA, Menko FH, Kluijt I, Taal BG, Gerritsma MA, Wever LD, et al. Colorectal cancer in the family: psychosocial distress and social issues in the years following genetic counselling. Hered Cancer Clin Pract 2007; 5: 59-66. http://dx. doi. org/10. 1186/1897-4287-5-2-59.
242. Esplen MJ, Butler K, Aronson M, Rothen-Mund H, Smith K, Way C, et al. Long term adjustment in individuals receiving genetic test results for hereditary non-polyposis colorectal cancer (HNPCC). Psychooncology 2007; 16: S135.
243. Curtis L. Unit Costs of Health and Social Care 2012. 20th edn. Canterbury: PSSRU, University of Kent; 2012.
244. UK Genetic Testing Network. Welcome to the UKGTN. 2012. URL: http://ukgtn. nhs. uk/(accessed July 2014).
245. Fireman B, Quesenberry C, Somkin C, Jacobson A, Baer D, West D. The Cost of Care for Cancer in a Health Maintenance Organization. Kaiser Permanente. Final report (contract NO1-CN-05224). Bethesda, MD: Applied Research Branch, National Cancer Institute; 1994.
246. Zauber AG, Lansdorp-Vogelaar I, Wilschut J, Knudsen AB, van Ballegooijen M, Kuntz KM. Cost-effectiveness of DNA Stool Testing to Screen for Colorectal Cancer: report to AHRQ and CMS from the Cancer Intervention and Surveillance Modeling Network (CISNET) for MISCAN and SimCRC Models. 2007. URL: www. cms. gov/medicare-coverage-database/details/technologyassessments-details. aspx?TAId=52 (accessed August 2014).
247. Ferro SA, Myer BS, Wolff DA, Poniewierski MS, Culakova E, Cosler LE, et al. Variation in the cost of medications for the treatment of colorectal cancer. Am J Manag Care 2008; 14: 717-25.
248. Lang K, Lines LM, Lee DW, Korn JR, Earle CC, Menzin J. Lifetime and treatment-phase costs associated with colorectal cancer: evidence from SEER-Medicare data. Clin Gastroenterol Hepatol 2009; 7: 198-204. http://dx. doi. org/10. 1016/j. cgh. 2008. 08. 034.
249. Yabroff KR, Warren JL, Schrag D, Mariotto A, Meekins A, Topor M, et al. Comparison of approaches for estimating incidence costs of care for colorectal cancer patients. Med Care 2009; 47: S56-63. http://dx. doi. org/10. 1097/MLR. 0b013e3181a4f482.
250. Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 1993; 31: 732-48. http://dx. doi. org/10. 1097/00005650-199308000-00006.
251. Pilgrim H, Tappenden P, Chilcott J, Bending M, Trueman P, Shorthouse A, et al. The costs and benefits of bowel cancer service developments using discrete event simulation. J Operat Res Soc 2009; 60: 1305-14. http://dx. doi. org/10. 1057/jors. 2008. 109.
252. Health and Social Care Information Centre. HRG4 Code to Group; HRG4 2011/12 Reference Costs Grouper. 2012. URL: www. hscic. gov. uk/article/2610/HRG4-201112-Reference-Costs-Grouper-Documentation (accessed July 2014).
253. National Institute for Health and Care Excellence. Laparoscopic Techniques for Hysterectomy (IPG239). London: National Institute for Health and Care Excellence; 2007.
254. Evidence for Policy and Practice Information and Co-ordinating Centre (EPPI-Centre). CCEMG-EPPI-Centre Cost Converter (v. 1. 2). 2013. URL: http://eppi. ioe. ac. uk/costconversion/default. aspx (accessed July 2014).
255. Medscape. Endometrial Cancer Treatment Protocols. 2011. URL: http://emedicine. medscape. com/article/2001830-overview (accessed July 2014).
256. Fleming GF, Brurietto VL, Cella D, Look KY, Reid GCH, Munkarah AR, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: A gynecologic oncology group study. J Clin Oncol 2004; 22: 2159-66. http://dx. doi. org/10. 1200/JCO. 2004. 07. 184.
257. Department of Health. NHS Reference Costs 2010-2011. 2011. URL: http://data. gov. uk/dataset/nhs-reference-costs-2010-11 (accessed July 2014).
258. Podczaski E, Kaminski P, Gurski K, MacNeill C, Stryker JA, Singapuri K, et al. Detection and patterns of treatment failure in 300 consecutive cases of 'early' endometrial cancer after primary surgery. Gynecol Oncol 1992; 47: 323-7. http://dx. doi. org/10. 1016/0090-8258(92)90134-5.
259. Shumsky AG, Stuart GC, Brasher PM, Nation JG, Robertson DI, Sangkarat S. An evaluation of routine follow-up of patients treated for endometrial carcinoma. Gynecol Oncol 1994; 55: 229-33. http://dx. doi. org/10. 1006/gyno. 1994. 1282.
260. Berchuck A, Anspach C, Evans AC, Soper JT, Rodriguez GC, Dodge R, et al. Postsurgical surveillance of patients with FIGO stage I/II endometrial adenocarcinoma. Gynecol Oncol 1995; 59: 20-4. http://dx. doi. org/10. 1006/gyno. 1995. 1262.
261. Reddoch JM, Burke TW, Morris M, Tornos C, Levenback C, Gershenson DM. Surveillance for recurrent endometrial carcinoma: development of a follow-up scheme. Gynecol Oncol 1995; 59: 221-5. http://dx. doi. org/10. 1006/gyno. 1995. 0012.
262. Owen P, Duncan ID. Is there any value in the long term follow up of women treated for endometrial cancer? Br J Obstet Gynaecol 1996; 103: 710-13. http://dx. doi. org/10. 1111/j. 1471-0528. 1996. tb09843. x.
263. Allsop JR, Preston J, Crocker S. Is there any value in the long-term follow up of women treated for endometrial cancer? Br J Obstet Gynaecol 1997; 104: 122. http://dx. doi. org/10. 1111/j. 1471-0528. 1997. tb10672. x.
264. Salvesen HB, Akslen LA, Iversen T, Iversen OE. Recurrence of endometrial carcinoma and the value of routine follow up. Br J Obstet Gynaecol 1997; 104: 1302-7. http://dx. doi. org/10. 1111/j. 1471-0528. 1997. tb10979. x.
265. Agboola OO, Grunfeld E, Coyle D, Perry GA. Costs and benefits of routine follow-up after curative treatment for endometrial cancer. CMAJ 1997; 157: 879-86.
266. Ng TY, Ngan HY, Cheng DK, Wong LC. Vaginal vault cytology in the routine follow-up of patients treated for endometrial carcinoma: is it useful? Aust N Z J Obstet Gynaecol 1997; 37: 104-6. http://dx. doi. org/10. 1111/j. 1479-828X. 1997. tb02229. x.
267. Gadducci A, Cosio S, Fanucchi A, Cristofani R, Genazzani AR. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer. Anticancer Res 2000; 20: 1977-84.
268. Morice P, Levy-Piedbois C, Ajaj S, Pautier P, Haie-Meder C, Lhomme C, et al. Value and cost evaluation of routine follow-up for patients with clinical stage I/II endometrial cancer. Eur J Cancer 2001; 37: 985-90. http://dx. doi. org/10. 1016/S0959-8049(01)00066-1.
269. Tjalma WAA, Van Dam PA, Makar AP, Cruickshank DJ. The clinical value and the cost-effectiveness of follow-up in endometrial cancer patients. Int J Gynecol Cancer 2004; 14: 931-7. http://dx. doi. org/10. 1111/j. 1048-891X. 2004. 014532. x.
270. Briggs AH, Claxton K, Sculpher MJ. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press; 2006.
271. Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD, et al. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Making 2012; 32: 722-32. http://dx. doi. org/10. 1177/0272989X12458348.
272. Thompson BA, Spurdle AB, Plazzer JP, Greenblatt MS, Akagi K, Al-Mulla F, et al. Application of a 5-tiered scheme for standardized classification of 2, 360 unique mismatch repair gene variants in the InSiGHT locus-specific database. Nat Genet 2014; 46: 107-15. http://dx. doi. org/10. 1038/ng. 2854.
273. Crépin M, Dieu M-C, Lejeune S, Escande F, Boidin D, Porchet N, et al. Evidence of constitutional MLH1 epimutation associated to transgenerational inheritance of cancer susceptability. Hum Mutat 2012; 33: 180-8. http://dx. doi. org/10. 1002/humu. 21617.
274. Huth C, Kloor M, Voigt AY, Bozukova G, Evers C, Gaspar H, et al. The molecular basis of EPCAM expression loss in Lynch syndrome-associated tumors. Mod Pathol 2012; 25: 911-16. http://dx. doi. org/10. 1038/modpathol. 2012. 30.
275. Kwon JS, Daniels MS, Sun CC, Lu KH. Preventing future cancers by testing women with ovarian cancer for BRCA mutations. J Clin Oncol 2010; 28: 675-82. http://dx. doi. org/10. 1200/JCO. 2008. 21. 4684.
276. Doust JA, Pietrzak E, Sanders S, Glasziou PP. Identifying studies for systematic reviews of diagnostic tests was difficult due to the poor sensitivity and precision of methodologic filters and the lack of information in the abstract. J Clin Epidemiol 2005; 58: 444-9. http://dx. doi. org/10. 1016/j. jclinepi. 2004. 09. 011.
277. Leeflang MM, Scholten RJ, Rutjes AW, Reitsma JB, Bossuyt PM. Use of methodological search filters to identify diagnostic accuracy studies can lead to the omission of relevant studies. J Clin Epidemiol 2006; 59: 234-40. http://dx. doi. org/10. 1016/j. jclinepi. 2005. 07. 014.
278. Bayliss SE, Davenport C. Locating systematic reviews of test accuracy studies: how five specialist review databases measure up. Int J Technol Assess Health Care 2008; 22: 39-46.
279. Glanville J, Paisley S. Identifying economic evaluations for health technology assessment. Int J Technol Assess Health Care 2010; 26: 436-40. http://dx. doi. org/10. 1017/S0266462310000991.
280. Sassi F, Archard L, McDaid D. Searching literature databases for health care economic evaluations: how systematic can we afford to be? Med Care 2002; 40: 387-94. http://dx. doi. org/10. 1097/00005650-200205000-00004.
281. Glanville J, Kaunelis D, Mensinkai S. How well do search filters perform in identifying economic evaluations in MEDLINE and EMBASE. Int J Technol Assess Health Care 2009; 25: 522-9. http://dx. doi. org/10. 1017/S0266462309990523.
282. Choi YH, Cotterchio M, McKeown-Eyssen G, Neerav M, Bapat B, Boyd K, et al. Penetrance of colorectal cancer among MLH1MSH2 carriers participating in the colorectal cancer familial registry in Ontario. Hered Cancer Clin Pract 2009; 7: 14. http://dx. doi. org/10. 1186/1897-4287-7-14.
283. Bermejo JL, Eng C, Hemminki K. Cancer characteristics in Swedish families fulfilling criteria for hereditary nonpolyposis colorectal cancer. Gastroenterology 2005; 129: 1889-99. http://dx. doi. org/10. 1053/j. gastro. 2005. 09. 012.
284. Hampel H, Stephens JA, Pukkala E, Sankila R, Aaltonen LA, Mecklin JP, et al. Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology 2005; 129: 415-21. http://dx. doi. org/10. 1016/j. gastro. 2005. 05. 011.
285. Plaschke J, Engel C, Kruger S, Holinski-Feder E, Pagenstecher C, Mangold E, et al. Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium. J Clin Oncol 2004; 22: 4486-94. http://dx. doi. org/10. 1200/JCO. 2004. 02. 033.
286. Vasen HF, Stormorken A, Menko FH, Nagengast FM, Kleibeuker JH, Griffioen G, et al. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol 2001; 19: 4074-80.
287. Watson P, Lin KM, Rodriguez-Bigas MA, Smyrk T, Lemon S, Shashidharan M, et al. Colorectal carcinoma survival among hereditary nonpolyposis colorectal carcinoma family members. Cancer 1998; 83: 259-66. http://dx. doi. org/10. 1002/(SICI)1097-0142(19980715)83: 2<259:: AID-CNCR9>3. 0. CO; 2-L.
288. Sankila R, Aaltonen LA, Jarvinen HJ, Mecklin JP. Better survival rates in patients with MLH1-associated hereditary colorectal cancer. Gastroenterology 1996; 110: 682-7. http://dx. doi. org/10. 1053/gast. 1996. v110. pm8608876.
289. Bertario L, Russo A, Sala P, Eboli M, Radice P, Presciuttini S, et al. Survival of patients with hereditary colorectal cancer: comparison of HNPCC and colorectal cancer in FAP patients with sporadic colorectal cancer. Int J Cancer 1999; 80: 183-7. http://dx. doi. org/10. 1002/(SICI)1097-0215(19990118)80: 2<183:: AID-IJC4>3. 0. CO; 2-W.
290. Elsakov P, Kurtinaitis J. Survival from colorectal carcinoma in HNPCC families as compared to the general population in Lithuania-initial results. Fam Cancer 2006; 5: 369-71. http://dx. doi. org/10. 1007/s10689-006-0007-7.
291. Fujita S, Moriya Y, Sugihara K, Akasu T, Ushio K. Prognosis of hereditary nonpolyposis colorectal cancer (HNPCC) and the role of Japanese criteria for HNPCC. Jpn J Clin Oncol 1996; 26: 351-5. http://dx. doi. org/10. 1093/oxfordjournals. jjco. a023244.
292. Haghighi MM, Vahedi M, Mohebbi SR, Pourhoseingholi MA, Fatemi SR, Zali MR. Comparison of survival between patients with hereditary non polyposis colorectal cancer (HNPCC) and sporadic colorectal cancer. Asian Pac J Cancer Prev 2009; 10: 209-12.
293. Myrhøj T, Bisgaard ML, Bernstein I, Svendsen LB, Sondergaard JO, Bulow S. Hereditary non-polyposis colorectal cancer: clinical features and survival. Results from the Danish HNPCC register. Scand J Gastroenterol 1997; 32: 572-6. http://dx. doi. org/10. 3109/00365529709025102.
294. Percesepe A, Benatti P, Roncucci L, Sassatelli R, Fante R, Ganazzi D, et al. Survival analysis in families affected by hereditary non-polyposis colorectal cancer. Int J Cancer 1997; 71: 373-6. http://dx. doi. org/10. 1002/(SICI)1097-0215(19970502)71: 3<373:: AID-IJC12>3. 0. CO; 2-H.
295. Stigliano V, Assisi D, Cosimelli M, Palmirotta R, Giannarelli D, Mottolese M, et al. Survival of hereditary non-polyposis colorectal cancer patients compared with sporadic colorectal cancer patients. J Exp Clin Cancer Res 2008; 27: 39. http://dx. doi. org/10. 1186/1756-9966-27-39.
296. You JF, Hsieh LL, Changchien CR, Chen JS, Chen JR, Chiang JM, et al. Inverse effects of mucin on survival of matched hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer patients. Clin Cancer Res 2006; 12: 4244-50. http://dx. doi. org/10. 1158/1078-0432. CCR-06-0202.
297. Russo A, Sala P, Alberici P, Gazzoli I, Radice P, Montefusco C, et al. Prognostic relevance of MLH1 and MSH2 mutations in hereditary non-polyposis colorectal cancer patients. Tumori 2009; 95: 731-8.
298. Guillen-Ponce C, Martinez-Sevila C, Perea R, Arenas M, Molina-Garrido MJ, Goicoechea M, et al. Gynecologic cancer screening in women at high risk of Lynch syndrome. J Clin Oncol 2011; 29: 1559.
299. Helder-Woolderink JM, De Bock GH, Hollema H, Hofstra RMW, Sijmons RH, Mourits MJE. Annual gynaecological surveillance in women with Lynch syndrome: What's the additional value of microcurettage? Int J Gynecol Cancer 2011; 21: S1067.
300. Schorge JO, Modesitt SC, Coleman RL, Cohn DE, Kauff ND, Duska LR, et al. SGO white paper on ovarian cancer: Aetiology, screening and surveillance. Gynecol Oncol 2010; 119: 7-18. http://dx. doi. org/10. 1016/j. ygyno. 2010. 06. 003.
301. Wood NJ, Duffy SR, Sheridan E, Thomas HJW, Dove-Edwin I, Goff S, et al. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma (multiple letters). Cancer 2003; 98: 1772-4. http://dx. doi. org/10. 1002/cncr. 11704.
302. Boston Medical Center. IPAA Procedure. 2013. URL: www. bmc. org/ipaa/procedure. htm (accessed July 2014).
303. Bouzourene H, Hutter P, Losi L, Martin P, Benhattar J. Selection of patients with germline MLH1 mutated Lynch syndrome by determination of MLH1 methylation and BRAF mutation. Fam Cancer 2010; 9: 167-72. http://dx. doi. org/10. 1007/s10689-009-9302-4.
304. Chang SC, Lin PC, Yang SH, Wang HS, Liang WY, Lin JK. Taiwan hospital-based detection of Lynch syndrome distinguishes 2 types of microsatellite instabilities in colorectal cancers. Surgery 2010; 147: 720-8. http://dx. doi. org/10. 1016/j. surg. 2009. 10. 069.